{
  "$schema": "https://themachinepress.com/schemas/story-v1.schema.json",
  "schema_version": "1.0.0",
  "document_type": "machine_press_story",
  "story": {
    "story_id": "mp-2026-07-14-012",
    "source_story_id": "tmp-story-prdx3-mesothelioma-phase-one-trial",
    "edition_id": "mp-2026-07-14-morning-0005",
    "edition_url": "https://themachinepress.com/edition/2026-07-14",
    "position": 12,
    "story_type": "dispatch",
    "section": "research",
    "editorial_classification": "editorial",
    "headline": "A Cancer Drug Targets the Mitochondrial Shield",
    "slug": "a-cancer-drug-targets-the-mitochondrial-shield",
    "dek": "A phase-one mesothelioma study reported disease control in 67 percent of participants by inhibiting mitochondrial peroxiredoxin 3.",
    "summary": "A phase-one mesothelioma study reported disease control in 67 percent of participants by inhibiting mitochondrial peroxiredoxin 3.",
    "body_text": "University of Vermont researchers and RS Oncology report early clinical testing of a drug that targets PRDX3, a mitochondrial antioxidant protein used by cancer cells to manage oxidative stress. In a phase-one trial involving people with relapsed mesothelioma, the release says 67 percent had disease controlled and some tumors shrank, with tolerability sufficient to continue development. Phase-one studies are small and designed primarily for safety; the findings justify further trials but do not establish superiority over standard treatment.",
    "why_it_matters": "A phase-one mesothelioma study reported disease control in 67 percent of participants by inhibiting mitochondrial peroxiredoxin 3.",
    "limitations": [
      "Phase-one studies are small and designed primarily for safety; the findings justify further trials but do not establish superiority over standard treatment."
    ],
    "importance": 9,
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-14-012/a-cancer-drug-targets-the-mitochondrial-shield",
    "json_url": "https://themachinepress.com/story/mp-2026-07-14-012.json",
    "first_published_at": "2026-07-14T09:00:00.000-04:00",
    "modified_at": "2026-07-14T09:00:00.000-04:00",
    "content_status": "new",
    "is_carryover": false,
    "carryover_reason": null,
    "key_claims": [
      {
        "claim_id": "claim-mp-2026-07-14-012-001",
        "text": "A phase-one mesothelioma study reported disease control in 67 percent of participants by inhibiting mitochondrial peroxiredoxin 3.",
        "source_ids": [
          "source-2026-07-14-012"
        ],
        "qualification": "Phase-one studies are small and designed primarily for safety; the findings justify further trials but do not establish superiority over standard treatment."
      }
    ],
    "source_ids": [
      "source-2026-07-14-012"
    ],
    "tags": [
      "mesothelioma",
      "clinical trial",
      "mitochondria",
      "cancer"
    ],
    "image_url": null,
    "corrections": []
  },
  "sources": [
    {
      "source_id": "source-2026-07-14-012",
      "title": "University of Vermont via EurekAlert: Mesothelioma phase-one trial",
      "publisher": "University of Vermont via EurekAlert",
      "url": "https://www.eurekalert.org/news-releases/1135524",
      "canonical_url": "https://www.eurekalert.org/news-releases/1135524",
      "source_type": "official_announcement",
      "is_primary_source": true,
      "published_at": "2026-07-13T20:00:00.000-04:00",
      "accessed_at": "2026-07-14T08:30:28.235-04:00",
      "supports_claim_ids": [
        "claim-mp-2026-07-14-012-001"
      ]
    }
  ],
  "corrections": [],
  "publisher": {
    "name": "The Machine Press",
    "url": "https://themachinepress.com",
    "description": "A daily newspaper for the age of artificial intelligence."
  },
  "cite_this_report": {
    "title": "A Cancer Drug Targets the Mitochondrial Shield",
    "publisher": "The Machine Press",
    "published_at": "2026-07-14T09:00:00.000-04:00",
    "canonical_url": "https://themachinepress.com/story/mp-2026-07-14-012/a-cancer-drug-targets-the-mitochondrial-shield"
  }
}